Methodological considerations in defining CBL as a prognostic biomarker in stage II melanoma. Han J, Gao X, Jiang W. Br J Cancer 2026 Sep 21. doi: 10.1038/s41416-026-03628.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Han J, Gao X, Jiang W. Methodological considerations in defining CBL as a prognostic biomarker in stage II melanoma. Br J Cancer 2026 Sep 21. doi: 10.1038/s41416-026-03628.
PMID: 42768151